This article was originally published in The Gray Sheet
Executive SummaryRoche completes $3.4 billion acquisition of tissue-based cancer test maker Ventana Medical Systems Feb. 19. The firms inked the definitive $89.50-per-share merger deal Jan. 21 (1"The Gray Sheet" Jan. 28, 2008, p. 4)
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.